Abstract
A large number of herbal remedies (e.g. garlic, mistletoe, Essiac, Lingzhi, and astragalus) are used by cancer patients for treating the cancer and/or reducing the toxicities of chemotherapeutic drugs. Some herbal medicines have shown potentially beneficial effects on cancer progression and may ameliorate chemotherapy-induced toxicities. However, there is no or weak scientific basis for the clinical use of these herbal medicines in cancer management and almost none of these plant medicines have been tested in rigorous clinical trials. There are increased reports on the interaction of herbal medicines and anticancer drugs that is becoming a safety concern. For example, a clinical study in cancer patients reported that treatment of St Johns wort at 900 mg/day orally for 18 days decreased the plasma levels of the active metabolite of irinotecan, SN-38, by 42%. In healthy subjects, 2 weeks of treatment with St Johns wort at 900 mg/day significantly decreased the systemic exposure of imatinib by 32%. In women with advanced breast cancer, coadministration of garlic supplement reduced the clearance of docetaxol by 23.1-35.1%, although the difference did not achieve statistical significance. Most anticancer drugs undergo Phase I and/or II metabolism and are substrates of P-glycoprotein, breast cancer resistance protein, multidrug resistance associated proteins, and/or other transporters. Induction and inhibition of these enzymes and transporters are considered as important mechanisms for herb-anticancer drug interactions. Further studies are warranted to investigate potentially harmful herbal interactions with anticancer drugs in patients.
Keywords: Anticancer drug, herbal medicine, herb-drug interaction, toxicity, pharmacokinetics, cytochrome P450, P-glycoprotein, St John's wort, drug resistance
Current Medicinal Chemistry
Title: Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical Considerations
Volume: 17 Issue: 16
Author(s): An-Kui Yang, Shu-Ming He, Liang Liu, Jun-Ping Liu, Ming Qian Wei and Shu-Feng Zhou
Affiliation:
Keywords: Anticancer drug, herbal medicine, herb-drug interaction, toxicity, pharmacokinetics, cytochrome P450, P-glycoprotein, St John's wort, drug resistance
Abstract: A large number of herbal remedies (e.g. garlic, mistletoe, Essiac, Lingzhi, and astragalus) are used by cancer patients for treating the cancer and/or reducing the toxicities of chemotherapeutic drugs. Some herbal medicines have shown potentially beneficial effects on cancer progression and may ameliorate chemotherapy-induced toxicities. However, there is no or weak scientific basis for the clinical use of these herbal medicines in cancer management and almost none of these plant medicines have been tested in rigorous clinical trials. There are increased reports on the interaction of herbal medicines and anticancer drugs that is becoming a safety concern. For example, a clinical study in cancer patients reported that treatment of St Johns wort at 900 mg/day orally for 18 days decreased the plasma levels of the active metabolite of irinotecan, SN-38, by 42%. In healthy subjects, 2 weeks of treatment with St Johns wort at 900 mg/day significantly decreased the systemic exposure of imatinib by 32%. In women with advanced breast cancer, coadministration of garlic supplement reduced the clearance of docetaxol by 23.1-35.1%, although the difference did not achieve statistical significance. Most anticancer drugs undergo Phase I and/or II metabolism and are substrates of P-glycoprotein, breast cancer resistance protein, multidrug resistance associated proteins, and/or other transporters. Induction and inhibition of these enzymes and transporters are considered as important mechanisms for herb-anticancer drug interactions. Further studies are warranted to investigate potentially harmful herbal interactions with anticancer drugs in patients.
Export Options
About this article
Cite this article as:
Yang An-Kui, He Shu-Ming, Liu Liang, Liu Jun-Ping, Qian Wei Ming and Zhou Shu-Feng, Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical Considerations, Current Medicinal Chemistry 2010; 17 (16) . https://dx.doi.org/10.2174/092986710791111279
DOI https://dx.doi.org/10.2174/092986710791111279 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Recent Developments in Positron Emission Tomography Technology
Recent Patents on Medical Imaging Cyclopamine, a Naturally Occurring Alkaloid, and Its Analogues May Find Wide Applications in Cancer Therapy
Current Topics in Medicinal Chemistry Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Trends in Biotechnological Drugs for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery KiSS1-Induced GPR54 Signaling Inhibits Breast Cancer Cell Migration and Epithelial-Mesenchymal Transition via Protein Kinase D1
Current Molecular Medicine Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis The Role of Estrogen and Estrogen-Related Drugs in Cardiovascular Diseases
Current Drug Metabolism Use of Gadoxetic Acid-enhanced MRI to Predict the Development of Postoperative Pancreatic Fistulas by Estimating the Degree of Pancreatic Fibrosis
Current Medical Imaging Targeting Breast Cancer Cells with G4 PAMAM Dendrimers and Valproic Acid Derivative Complexes
Anti-Cancer Agents in Medicinal Chemistry Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets TGF-β Pathway as a Therapeutic Target in Bone Metastases
Current Pharmaceutical Design Patent Perspective for Potential Antioxidant Compounds-Rutin and Quercetin
Recent Patents on Nanomedicine The Proteins of Plant Defensin Family and their Application Beyond Plant Disease Control
Recent Patents on DNA & Gene Sequences Heparan Sulfate Proteoglycans, Tumour Progression and the Cancer Stem Cell Niche
Current Cancer Therapy Reviews The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets Liposomes as Anticancer Therapeutic Drug Carrier’s Systems: More than a Tour de Force
Current Nanomedicine Engineered Silver Nanoparticles, A New Nanoweapon Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Chemoradiotherapy in Rectal Cancer
Current Drug Therapy The Potential and Rationale for COX-2 Inhibitors in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry